MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting

05.12.2022 - MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company creating innovative medical solutions ... Seite 1

Related Keywords

Japan ,Japanese , ,Kyowa Kirin Co Ltd ,Oncology Drugs Advisory Committee ,Drug Administration ,Pharma Inc ,Nasdaq ,Kyowa Kirin ,Yoshifumi Torii ,Drugs Advisory Committee ,Mei Pharma ,